The estimated Net Worth of Luke M Beshar is at least $2.85 Million dollars as of 30 June 2022. Mr. Beshar owns over 10,000 units of Regenxbio Inc stock worth over $2,516,580 and over the last 22 years he sold RGNX stock worth over $0. In addition, he makes $333,316 as Independent Director at Regenxbio Inc.
Sign up
Mr. Beshar RGNX stock SEC Form 4 insiders trading
Luke has made over 6 trades of the Regenxbio Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of RGNX stock worth $31,000 on 30 June 2022.
The largest trade he's ever made was exercising 33,292 units of Regenxbio Inc stock on 19 November 2018 worth over $480,071. On average, Luke trades about 2,610 units every 36 days since 2003. As of 30 June 2022 he still owns at least 198,000 units of Regenxbio Inc stock.
You can see the complete history of Mr. Beshar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Luke Beshar biography
Luke M. Beshar CPA serves as Independent Director of the Company. He has been a Director since April 2015. Mr. Beshar is a former Chief Financial Officer of various public and private companies and has more than 30 years of general and financial management experience. Mr. Beshar served as the Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc. from November 2007 to February 2015 and as Executive Vice President and Chief Financial Officer of Cambrex Corporation, a life sciences company, from December 2002 to November 2007. Mr. Beshar began his career with Arthur Andersen & Co. in 1980 and is a Certified Public Accountant. Mr. Beshar has served as a director and chair of the audit committee at Trillium Therapeutics Inc., a publicly held immuno-oncology company, since March 2014, and a director at Artara Therapeutics, a privately held company focused on rare diseases, since October 2018. Mr. Beshar holds a B.S. degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia. Mr. Beshar’s qualifications to continue to serve as a member of the Board include his financial and managerial experience in the biotechnology and life sciences industries, including serving as Chief Financial Officer, his financial and accounting expertise and his prior service on public and private company boards.
What is the salary of Luke Beshar?
As the Independent Director of Regenxbio Inc, the total compensation of Luke Beshar at Regenxbio Inc is $333,316. There are 12 executives at Regenxbio Inc getting paid more, with Kenneth Mills having the highest compensation of $6,147,270.
How old is Luke Beshar?
Luke Beshar is 62, he's been the Independent Director of Regenxbio Inc since 2015. There are 7 older and 11 younger executives at Regenxbio Inc. The oldest executive at Regenxbio Inc is Allan Fox, 72, who is the Chairman of the Board.
What's Luke Beshar's mailing address?
Luke's mailing address filed with the SEC is C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010.
Insiders trading at Regenxbio Inc
Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas, and Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.
What does Regenxbio Inc do?
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
What does Regenxbio Inc's logo look like?
Complete history of Mr. Beshar stock trades at Regenxbio Inc, Trillium Therapeutics Inc, and Protara Therapeutics Inc
Regenxbio Inc executives and stock owners
Regenxbio Inc executives and other stock owners filed with the SEC include:
-
Kenneth Mills,
President, Chief Executive Officer, Executive Director -
Steve Pakola,
Senior Vice President, Chief Medical Officer -
Vittal Vasista,
Chief Financial Officer, Senior Vice President -
Olivier Danos,
Senior Vice President, Chief Scientific Officer -
Curran Simpson,
Senior Vice President - Product Development, Chief Technology Officer -
Kenneth T. Mills,
Pres, CEO & Director -
Vittal K. Vasista,
Chief Financial Officer -
Dr. Olivier Danos Ph.D.,
Chief Scientific Officer -
Curran M. Simpson M.S.,
Chief Operations & Technology Officer -
Patrick J. Christmas II, J.D.,
Chief Legal Officer -
Patrick J. Christmas II,
Chief Legal Officer -
Dr. Stephen Pakola,
Chief Medical Officer -
Luke Beshar,
Independent Director -
David Stump,
Independent Director -
Daniel Abdun-Nabi,
Independent Director -
A. N. Karabelas,
Lead Independent Director -
Daniel Tasse,
Independent Director -
Alexandra Glucksmann,
Independent Director -
Allan Fox,
Chairman of the Board -
Dr. Laura A. Coruzzi J.D., Ph.D.,
Sr. VP of Intellectual Property -
Ram Palanki,
Sr. VP of Commercial Strategy & Operations -
Dr. Laura A. Coruzzi,
Sr. VP of Intellectual Property -
Shiva G. Fritsch,
Chief People Officer -
Andrew Yost,
VP of Corp. Devel. -
Tricia Truehart,
VP of Investor Relations & Corp. Communications -
Stephen Yoo,
Chief Medical Officer -
Llc Fmr,
10% owner -
Camille D Samuels,
Director -
Faraz Ali,
Chief Business Officer -
Edgar Engleman,
Director -
James E Deerfield Mgmt L.P....,
-
Donald J Jr Hayden,
-
Patrick J. Christmas,
Chief Legal Officer -
Jean Bennett,
-
George V Migausky,
-
Jennifer Zachary,